Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hanks GE, Hanlon AL, Epstein B, Horwitz EM (2002) Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys 54:427–435
Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71:1028–1033
Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487
Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996
Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74
Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101
Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031
Lukka H, Hayter C, Julian JA et al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132–6138
Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518–526
Yeoh EE, Holloway RH, Fraser RJ et al (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66:1072–1083
Dasu A (2007) Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19:289–301
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82:e17–e24
Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33:481–488
Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R (2010) Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 9:473–477
Freeman DE, King CR (2011) Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 6:3
Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM (2009) Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8:387–392
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M (2010) Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1
King CR, Brooks JD, Gill H, Presti JC Jr (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877–882
McBride SM, Wong DS, Dombrowski JJ et al (2011) Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. doi: 10.1002/cncr.26699
Kang JK, Cho CK, Choi CW et al (2011) Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 97:43–48
Boike TP, Lotan Y, Cho LC et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026
Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67:1099–1105
Zelefsky MJ, Shi W, Yamada Y et al (2009) Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75:1350–1356
Lamb DS, Denham JW, Joseph D et al (2011) A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys 79:385–391
Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419
Katz A, Santoro M, Diblasio F. (2012) Four year outcomes and quality of life following stereotactic body radiation therapy: a rapid, non-invasive alternative for the treatment of intermediate-risk organ confined prostate cancer. Oral presentation at the American Urological Association annual meeting; 1478. Atlanta, GA, 19–22 May 2012
Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105
Katz AJ, Santoro M, Ashley R, Diblasio F (2011) Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: is there a dose effect? Front Oncol 1:49
Eade T, Horwitz E, Ruth K et al (2008) A Comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or 125 I permanent implant. Int J Radiat Oncol Biol Phys 71:338–345